Combination therapy is not associated with improved rates of clinical or endoscopic remission in patients with inflammatory bowel disease treated with ustekinumab or vedolizumab: a retrospective study

BACKGROUND: Management of inflammatory bowel disease (IBD) involves biological agents, often in combination with thiopurines or methotrexate. The aim of our study was to compare clinical and endoscopic outcomes in IBD patients treated with vedolizumab or ustekinumab, as monotherapy or in combination...

Descripción completa

Detalles Bibliográficos
Autores principales: Jeffrey, Angus W., Picardo, Sherman, Menon, Shankar, So, Kenji, Venugopal, Kannan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hellenic Society of Gastroenterology 2023
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10304522/
https://www.ncbi.nlm.nih.gov/pubmed/37396006
http://dx.doi.org/10.20524/aog.2023.0808

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10304522/
https://www.ncbi.nlm.nih.gov/pubmed/37396006
http://dx.doi.org/10.20524/aog.2023.0808

Ejemplares similares